一线治疗鼻咽癌 ！ 君实生物特瑞普利单抗获FDA突破性疗法认定
8月11日，君实生物表示其特瑞普利单抗（拓益）联合吉西他滨/顺铂作为晚期复发或转移性鼻咽癌患者的一线 […]
District Party Secretary Min Wang paying a visit to the China Australia Medical Innovation Park: An in-depth display of the “AI + health sciences” sector ecosystem
On the 22nd of July, Secretary of the District Par […]
To establish a trillion dollar-scale health sciences sector, Hangzhou is revamping and upgrading policies to aid Biomedical sciences again!
The General Office of the Hangzhou Municipal Peopl […]
Adelaide’s BioMed City is attracting strong clinical trial interest as its critical mass continues to grow
There has been a 50 per cent increase in clinical […]
(Recap) Successful conclusion to our “Tips to Efficiently Commence Clinical Trials in Australia” Webinar
Bioclub, in collaboration with BioHarbour, the Chi […]
ADC交易如火如荼：荣昌生物26亿美元license out创新纪录！
今年的创新药市场，ADC是其中最火热的细分领域之一，研发如火如荼，交易也如火如荼。 8月9日晚，荣昌 […]
两款新药获得CDE拟突破性疗法认定，来自复星凯特、GSK
可用于治疗非霍奇金淋巴瘤、乙肝
Illumina 二季度营收增长 78%，基因测序及癌症检测量回升
与 2020 年同期相比，Illumina所有国际地区也出现了强劲增长。
豪掷20亿美元！拜耳收购本欲IPO的小分子新药研发公司
当地时间8月5日，拜耳公司宣布，它将以15亿美元的预付款和5亿美元的里程碑付款收购癌症和免疫疾病药物 […]
禾木生物赴港IPO，高瓴创投、君联资本参投
2017年成立，历经4轮、总额1.38亿美元的融资后，禾木生物7月30日递交招股书，拟于港交所主板挂 […]
